Loading...
Predicting Corticosteroid Free Endoscopic Remission with Vedolizumab in Ulcerative Colitis
BACKGROUND: Vedolizumab is an effective therapy for ulcerative colitis (UC), but costly and slow to work. New clinical responses occur after 30 weeks of therapy. AIMS: We aimed to enable physicians, patients, and insurers to predict whether a patient with UC will respond to vedolizumab at an early t...
Na minha lista:
| Udgivet i: | Aliment Pharmacol Ther |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5814341/ https://ncbi.nlm.nih.gov/pubmed/29359519 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.14510 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|